Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Open accessAbstract
Pathological osteolyses are considered a consequence of a disturbance in the mechanisms that govern the bone remodeling, mainly the communication between osteoclasts and osteoblasts. Osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) are newly discovered molecules that play a key role in these communications. RANKL is essential for osteoclast differentiation via its receptor RANK located on the osteoclast membrane. OPG is a soluble decoy receptor that inhibits osteoclast differentiation through its binding to RANKL. The aim of this study is the analysis of the RANKL/OPG balance by complementary methods (semiquantitative reverse transcription-polymerase chain reaction, immunohistochemistry, and enzyme-linked immunosorbent assay) in human osteolysis associated to various bone etiologies (n = 60), tumoral (primitive, secondary) or not, compared to healthy tissues (n = 16). Results demonstrated that RANKL/OPG ratio was significantly increased in patients suffering from severe osteolysis compared to the control group and that this imbalance is involved in bone resorption mechanisms. In this study, OPG expression appears to reflect a protective mechanism of the skeleton to compensate increased bone resorption by inhibiting osteoclast formation and bone resorbing activity. Moreover, as revealed by immunohistochemistry, RANKL and OPG were colocalized in all of the tissues analyzed. To define the veracity of RANKL/OPG index in assessing and managing patients with severe osteolysis, an extended population of patients suffering from severe osteolysis must be now monitored.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Osteoclast activity likely depends at least in part on the relative balance between RANKL and OPG.
“Osteoclast activity is likely to depend, at least in part, on the relative balance of RANKL and OPG.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 42 · Cited by 282
Research works printed but not linked: 3
- Goltzman D, Karaplis AC, Kremer R, Rabbani SA: Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 2000, 88:2903-2908
- Conroy T, Mallissard L, Dartois D, Luporsi E, Stines J, Chardot C: Histoire naturelle et e ´volution des me ´tastases osseuses: a propos de 429 observations. Bull Cancer 1988, 75:845-857
- Guise TA: Molecular mechanisms of osteolytic bone metastases. Cancer 2000, 88:2892-2898
- Authors
- Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., & Heymann, D.
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Corresponding author
- Heymann, Dominique
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2003-11
- Volume
- 163
- Issue
- 5
- Pages
- 2021-2031
- ISSN
- 0002-9440 (ISSN-L)
- PMC
- PMC1892410
- OpenAlex
- W2018450202
- Cited by
- 282
- References
- 42
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 6 · 2023: 11 · 2022: 7 · 2021: 8 · 2020: 11 · 2019: 10 · 2018: 11 · 2017: 19 · 2016: 10 · 2015: 18 · 2014: 10 · 2013: 14 · 2012: 9
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal Of Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Ligue Contre le Cancer
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- RANKL/OPG ratio, osteolysis, osteoprotegerin, RANKL, bone remodeling, osteoclastogenesis, bone resorption, RANK receptor
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Carrier Proteins, Enzyme-Linked Immunosorbent Assay, Female, Glycoproteins, Humans, Immunohistochemistry, Male, Membrane Glycoproteins, Middle Aged, Osteoblasts, Osteoclasts, Osteolysis, RNA, Messenger, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Reverse Transcriptase Polymerase Chain Reaction, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
